Transcriptomic analysis revealed several promising hits, among which the galactosyltransferase GALNT7 was most striking: In patients suffering from pancreatic adenocarcinoma, a tumor type in which KRAS carries an activating mutation more than 90% of the time, GALNT7 was strongly correlated with patient survival, suggesting a relation between KRAS and GALNT7. Indeed, in KRASG12D expressing cells, siRNA-mediated knockdown of GALNT7 caused a strong reduction in glycocalyx height, indicating that GALNT7 is indeed a single-gene mediator of the effect of oncogenic KRAS onto the glycocalyx. Here, KRAS is linked to pancreatic adenocarcinoma.